Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.


Here you will find information and news about the latest events. In this way, you can stay ‘a heartbeat ahead’
of developments.

Also available as RSS feed for your RSS feed reader.

You can subscribe to our newsletter here:


On September 15 and 16, CARL Academy welcomed over 100 European ECPR and CARL experts to the first edition of the CARL Summit in Freiburg, Germany. In many inspiring presentations and discussions, the leading key opinion leaders in the field shared their expertise, recent experiences and tips and tricks for the successful realization of ECPR programs. An important step to shape the future of ECPR.

Learn more >
Family man survives thanks to CARL.

Jörg Teichfischer suffered a cardiac arrest at home in spring 2023. He was resuscitated by an emergency physician by means of defibrillator and cardiac massage for 55 minutes. Afterwards an ambulance took him to the Ortenau Klinikum Lahr, where resuscitative measures continued for almost 20 minutes.

Learn more >
Retiree back to life after cardiac arrest

Retiree back to life after cardiac arrest Our drive is to save lives and give patients suffering a cardiac arrest the chance to survive neurologically intact – anywhere in the world, in- and out-of-hospital. Our system joins the rescue chain and is being applied when, despite of all efforts, the heart cannot be restarted with…

Learn more >
31-year-old man survives cardiac arrest without neurological sequelae

In Europe, around 500,000 people suffer a sudden cardiac arrest every year. Outside of a hospital, only about 8% of those affected survive, and a high percentage of survivors suffer from neurological sequelae after resuscitation.

Learn more >
The CARL-Mobil in the rescue chain of Freiburg

When an emergency call is received at the integrated control center in Freiburg and a cardiac arrest, a secured resuscitation or a drowning accident is reported, the CARL-Mobil is alerted directly in addition to an ambulance and an emergency medical service vehicle. The concept of parallel alerting thus saves valuable minutes and shortens the time until the arrival of the treatment team.

Learn more >
CARL at DGIIN Congress in Berlin: Focus on extracorporeal resuscitation

“We are the team” was this year’s motto of the 54th Annual Meeting of the German Society of Internal Intensive and Emergency Medicine (DGIIN) and the Austrian Society of Internal and General Intensive and Emergency Medicine (ÖGIAIN) in Berlin. This motto was also a topic at the Resuscitec GmbH lunch symposium, which was attended by 80 participants. Physicians from hospitals in Germany and Austria spoke on the topic “CARL. The future of interdisciplinary resuscitation?”.

Learn more >
Strategic sales partnership between Resuscitec and WEINMANN Emergency  

With immediate effect WEINMANN Emergency distributes the CARL Technology of Resuscitec in France via its subsidiary WEINMANN Emergency France. CARL is an advanced concept for extracorporeal resuscitation of patients after cardiovascular arrest, which can be used both in-hospital and prehospital. 

Learn more >
„Freiburg model” for Life Saving of Resuscitation Patients

Yesterday, Florian Wahl, Chairman of the Committee for Social Affairs, Health and Integration in the State Parliament of Baden-Württemberg (BW), together with an SPD delegation from Freiburg and BW, visited the University Emergency Center of the Medical Center – University of Freiburg and the CARL Academy in the Güterhalle.

Learn more >
CARL. Anniversary at the EuroELSO in Lisbon

Exactly one year ago, CARL was presented for the first time to an international audience at EuroELSO 2022 in London. Exactly 12 months later, an extremely positive balance can be drawn after EuroELSO 2023 in Lisbon. With over 350 participants, the CARL Lunch Symposium on “CARL – The next level of ECPR?” was the best-attended industry symposium of the congress.

Learn more >
CARL in Lisbon: 11th Congress of the EuroELSO

The 11th Congress of the European Extracorporeal Life Support Organization (EuroELSO) will be held from April 26 to April 29 at the Congress Center in Lisbon.
Learn more about “CARL. The Next Level of ECPR” for controlled extracorporeal reperfusion with the goal of improving neurologically intact survival after cardiac arrest worldwide.

Learn more >